Adherence to anti-osteoporotic therapies: role and determinants of "spot therapy"

被引:19
作者
Tafaro, L. [1 ]
Nati, G. [2 ]
Leoni, E. [2 ]
Baldini, R. [3 ]
Cattaruzza, M. S. [4 ]
Mei, M. [2 ]
Falaschi, P. [1 ]
机构
[1] Univ Roma La Sapienza, St Andrea Hosp, Geriatr Unit, I-00189 Rome, Italy
[2] FIMMG, Rome, Italy
[3] Univ Roma La Sapienza, Dept Anat Histol Forens & Orthoped Sci, I-00189 Rome, Italy
[4] Univ Roma La Sapienza, Dept Publ Hlth & Infect Dis, I-00189 Rome, Italy
关键词
Adherence; Compliance; Osteoporosis; Persistence; Spot therapy; POSTMENOPAUSAL OSTEOPOROSIS; BISPHOSPHONATE THERAPY; FRACTURE OUTCOMES; PERSISTENCE; WOMEN; COMMUNICATION; REGIMENS;
D O I
10.1007/s00198-013-2283-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A successful therapy needs high level of adherence consisting in right drug intake in terms of persistence and compliance. Our study suggests adherence is higher if spot (less than 30 days) therapies are excluded; the analysis of spot therapy causes underlines the importance of the interpersonal aspects of medical practice. A successful therapy needs a high level of adherence consisting in right drug intake in terms of persistence and compliance. The aim of this study was to evaluate anti-osteoporotic therapies recorded in general practitioner databases in the area of Rome, which used the same computerized medical record management. The study focused on evaluating therapy adherence, any adherence changes excluding spot therapies (less than 30 days), and any cause of early therapy discontinuation in a subgroup of patients randomly selected. Thirty-one databases were evaluated, including a total of 6,390 anti-osteoporotic therapies: 5,853 were prescribed to women and 537 to men. The prescribed drugs were: vitamin D (13 %), calcium (8.7 %), vitamin D + calcium (40.1 %), raloxifene (3.3 %), alendronate (16.4 %), risedronate (7.7 %), clodronate (10.4 %), or other drugs (0.4 %). Spot therapies represented 53.7 % of the total prescriptions. The difference between adherence in the total group (24.64 %) and the group excluding spot therapies (43.38 %) is significant. The main factors influencing low adherence were side effects (27 %), misinformation given by the physician (17 %), insufficient motivation (9 %), difficult intake (9 %), and no perceived benefits (9 %). Our study suggests adherence is high and similar to other chronic diseases if spot therapies are excluded. The analysis of spot therapy causes suggests that an important role is played by the physician and the interpersonal aspects of medical practice, especially at the first prescriptions. The physician should collaborate with patients in choosing a personalized medical treatment. Reducing spot therapy could be the real goal in order to improve anti-osteoporotic therapy adherence.
引用
收藏
页码:2319 / 2323
页数:5
相关论文
共 21 条
[1]  
[Anonymous], 2003, Adherence to Long-Term Therapies: Evidence for action
[2]   Loss of treatment benefit due to low compliance with bisphosphonate therapy [J].
Beest, F. J. A. Penning-van ;
Erkens, J. A. ;
Olson, M. ;
Herings, R. M. C. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) :511-517
[3]   Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey [J].
Carr, A. J. ;
Thompson, P. W. ;
Cooper, C. .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (11) :1638-1644
[4]   Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis [J].
Cramer, JA ;
Amonkar, MM ;
Hebborn, A ;
Altman, R .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (09) :1453-1460
[5]   Variations in patients' adherence to medical recommendations - A quantitative review of 50 years of research [J].
DiMatteo, MR .
MEDICAL CARE, 2004, 42 (03) :200-209
[6]   Fracture outcomes related to persistence and compliance with oral bisphosphonates [J].
Gallagher, Arlene M. ;
Rietbrock, Stephan ;
Olson, Melvin ;
van Staa, Tjeerd P. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 (10) :1569-1575
[7]   META-ANALYSIS OF CORRELATES OF PROVIDER BEHAVIOR IN MEDICAL ENCOUNTERS [J].
HALL, JA ;
ROTER, DL ;
KATZ, NR .
MEDICAL CARE, 1988, 26 (07) :657-675
[8]   Partial adherence: a new perspective on health economic assessment in osteoporosis [J].
Kanis, J. A. ;
Cooper, C. ;
Hiligsmann, M. ;
Rabenda, V. ;
Reginster, J-Y. ;
Rizzoli, R. .
OSTEOPOROSIS INTERNATIONAL, 2011, 22 (10) :2565-2573
[9]   Compliance with drug therapies for the treatment and prevention of osteoporosis [J].
McCombs, JS ;
Thiebaud, P ;
McLaughlin-Miley, C ;
Shi, JH .
MATURITAS, 2004, 48 (03) :271-287
[10]   Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis [J].
Penning-van Beest, FJA ;
Goettsch, WG ;
Erkens, JA ;
Herings, RMC .
CLINICAL THERAPEUTICS, 2006, 28 (02) :236-242